BMC Cancer (Mar 2022)

Risk of developing depression among breast cancer patients in Palestine

  • Dana Sadaqa,
  • Ahlam Farraj,
  • Hani Naseef,
  • Hamza Alsaid,
  • Nimeh Al-Shami,
  • Abdallah Damin AbuKhalil

DOI
https://doi.org/10.1186/s12885-022-09420-8
Journal volume & issue
Vol. 22, no. 1
pp. 1 – 9

Abstract

Read online

Abstract Background Breast cancer (BC) is the most common cancer among women. Studies have shown that cancer patients can develop depression impacting their quality of life, treatment outcomes, and survival rates. This study aimed to determine the risk factors, severity and prevalence of depression among females diagnosed with BC in multiple hospitals across Palestine. Methods A cross-sectional study was conducted at different cancer treatment centers in Palestine using a previously developed questionnaire consisting of 23 questions to assess the severity of major depressive disorder among females diagnosed with breast cancer. The Patient Health Questionnaire-9 (PHQ-9) was included in the questionnaire. Results Out of 223 respondents, 79 (35.4%) have developed moderate to severe depression. Chi-square results revealed that the risk of developing moderate to severe depression was higher among females who suffer from side-effects related to BC treatment (P < 0.011), females who knew the BC stage at the diagnosis step (P < 0.031), and negative implications on BC patients in Palestine (P < 0.009). Conclusion Breast cancer patients have an increased risk of developing major depressive disorder. Patient assessment and treatment for depression at the time of BC diagnosis, during the treatment journey, and monitoring after treatment completion is essential for patient quality of life and BC treatment outcomes.

Keywords